ValuentumAd

Official PayPal Seal














Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Aug 3, 2017
Video: Explaining the Valuentum Buying Index
The Valuentum Buying Index (VBI) stands on the shoulders of giants in finance in uncovering investment ideas.
Aug 2, 2017
Valuentum's August Edition of Its Dividend Growth Newsletter
Image Source: Chris Potter. The link to download the August edition of the Dividend Growth Newsletter can be found in this article.
Aug 1, 2017
Apple, Hanesbrands Power Higher
Image shown: Performance of the S&P 500 SPDR (SPY) since the beginning of 2017. There aren’t two other companies within the Dividend Growth Newsletter portfolio that may be more controversial positions than Apple and Hanesbrands -- one is on the cutting edge of technology and the other makes T-shirts and underwear, a very interesting dichotomy.
Aug 1, 2017
Coca-Cola, Pepsi, Kimberly-Clark: Great Businesses But Lofty Earnings Multiples and Net Debt Positions
We love the business models of some of the most well-known consumer-staples equities, namely Coca-Cola, Pepsi, and Kimberly-Clark, but lofty earnings multiples and net debt positions complicate their investment prospects. Little to no top line growth only further muddies the picture.
Aug 1, 2017
Business Models of Garbage Haulers “Hitting on All Cylinders”
Image Source: Waste Connections. In a sign of the health of the US economy, garbage haulers are experiencing rates of top-line growth not witnessed in years, but their earnings multiples reflect share prices that may be disconnected from normalized fundamentals. No matter how much we love their business models, we’ve already “cashed in” our chips.
Aug 1, 2017
Amazon’s Free Cash Flow and Balance Sheet Health Impressive
Amazon’s share-price performance is a sign of these “frothy” times.
Aug 1, 2017
Intel’s Shares Trading at Huge Discount to Market
Image Source: Intel. Newsletter portfolio holding Intel continues to put up strong results, and the market is simply not giving it credit for them.
Jul 31, 2017
Newsletter Notifications -- July 31
We are making a number of changes to the newsletter portfolios today, July 31.
Jul 31, 2017
A Review of Johnson and Johnson’s Pharmaceutical Division
Image Source: J&J. Let’s take a deep dive into Johnson and Johnson’s pharmaceutical division Janssen Pharmaceuticals. Janssen traditionally serves as an area of clinical innovation adding an element of growth to the more stable product categories such as consumer health. However, there may be a few cracks in the Janssen revenue stream that could make growth at J&J harder to come by over the next few years.
Jul 31, 2017
Amgen’s Pipeline Continues to Disappoint
Image Source: Amgen. The ability to generate commercially-viable products via the clinical pipeline is crucial to grow profits and offset revenue declines from the loss of patent protection. We remain unimpressed with the progress shown thus far by biotech stalwart Amgen. Let’s review the clinical pipeline along with a consideration of the recently-released earnings report.



The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.